Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

Central Neuropathic Pain Clinical Trial

Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China

Status Not yet recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06422117
Study type	Interventional
Source	Haisco Pharmaceutical Group Co., Ltd.
Contact
Status	Not yet recruiting
Phase	Phase 3
Start date	May 30, 2024
Completion date	August 7, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01324232` - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis	Phase 2
Recruiting	`NCT06071949` - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis	Phase 3
Recruiting	`NCT06072001` - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis	Phase 3
Recruiting	`NCT05357066` - Nitrous Oxide as Treatment for Fibromyalgia	Phase 2
Completed	`NCT03901352` - Study of Mirogabalin for Central Neuropathic Pain	Phase 3
Not yet recruiting	`NCT04665492` - EEG Predictors of Neuropathic Pain in SCI
Completed	`NCT00313820` - Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain	Phase 4
Completed	`NCT02218203` - Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial	Phase 2